The HDM2 protein is a key regulator of the tumour suppressor, p53. Control of HDM2 function is critical for normal cell proliferation and stress responses, and it is becoming evident that multiple modi®cations of HDM2 can regulate its function within cells. In this study we show that HDM2 associated with the serinethreonine kinase, Akt, in response to growth factor stimulation of human primary cells. This association was concurrent with phosphorylation of Akt (at Ser 473), and resulted in elevated expression of HDM2 and enhanced nuclear localization. However, analysis of HDM2 proteins mutated at the consensus Akt recognition sites at serines 166 and 186 indicated that modi®cation at these residues was not sucient for the increased expression of the protein, which was blocked by the PI3 kinase inhibitor LY294002. Tryptic peptide and mutational analyses revealed evidence for an Akt phosphorylation site in HDM2 additional to the two consensus sites.
Introduction
The mdm2 gene was originally identi®ed as an ampli®ed gene in the spontaneously transformed cell line 3T3DM (Cahilly-Snyder et al., 1987) . These cells formed tumours when injected into nude mice, suggesting that mdm2 has proto-oncogenic capability. This was supported by the observations that overexpression of MDM2 promotes tumorigenesis in Rat2 or NIH3T3 cells lines (Fakharzadeh et al., 1991) , and cooperates with ras to promote transformation of primary rodent cells (Finlay, 1993) . Transcription of mdm2 can be induced by conditionally activate Raf, and the mdm2 promoter has been shown to be a target of the Ras/MEK/MAP kinase pathway (Ries et al., 2000) . The central mechanism underlying mdm2's transforming capabilities came from the observations that the Mdm2 protein, is a major regulator of the tumour suppressor protein, p53 (Kubbutat and Vousden, 1998) . Hdm2, the human counterpart, is ampli®ed in over 30% of human sarcomas, and further supports its role as a proto-oncogene (Oliner et al., 1992) .
Hdm2 encodes a protein containing several functional domains. The N-terminal region contains the p53-binding region (residues 26 ± 108) Picksley et al., 1994) . The central region contains a short highly acidic region, that regulates transcriptional activity (residues 211 ± 299) (Leveillard and Wasylyk, 1997; Thut et al., 1997) and the C-terminus contains a RING ®nger domain (residues 442 ± 481) important for E3 ligase activity and ubiquitin-mediated degradation of p53 (Fang et al., 2000; Honda and Yasuda, 2000) . The C-terminus has also been shown to be modi®ed by SUMO (Buschmann et al., 2000) . HDM2 contains several cellular localization sequences, there is a nuclear localization sequence (NLS, residues 178 ± 182) (Olson et al., 1993) , a nuclear export sequence (NES, residues 183 ± 195) (Roth et al., 1998) and a nucleolar localization sequence (NoLS, residues) (Lohrum et al., 2000; Weber et al., 2000) .
HDM2 negatively regulates both p53 activity and stability by directly binding to p53 within its Nterminal transactivation domain (residues 19 ± 26), targeting it for ubiquitin-mediated degradation by the proteosome. The hdm2 gene is itself transcriptionally activated by p53, and under normal conditions, the two proteins form a regulatory feedback loop (Freedman et al., 1999) . Under conditions of cellular stress, this feedback loop is disrupted to mediate the rapid stabilization and activation of p53 by a variety of mechanisms that are dependent on the particular type of stress. Many of these mechanisms converge on HDM2 itself, and involve regulation of mRNA expression, nucleolar sequestration, and post-translational modi®cation (Woods and Vousden, 2001) .
In recent months attention has turned to the potential role of phosphorylation in the regulation of HDM2 function. HDM2 is phosphorylated at multiple sites in vivo (Hay and Meek, 2000) . Phosphorylation by DNA-dependent protein kinase (DNA ± PK) (Mayo et al., 1997) casein kinase 2 (CK2) (Gotz et al., 1999; Guerra et al., 1997) , ATM kinase (Khosravi et al., 1999; Maya et al., 2001 ) and cyclin A-CDK complexes (Zhang and Prives, 2001 ) has been shown to modulate HDM2 function.
Since it is clear that cellular mechanisms exist to regulate HDM2 localization and degradation function under conditions of cellular stress, we wanted to explore the possibility that cellular mechanisms also exist to regulate HDM2 function under normal conditions. We show here, that HDM2 associates with the serine-threonine kinase, Akt in response to growth factor stimulation of normal cells, and association is concurrent with Akt phosphorylation. This response correlated with induction of HDM2, but this is not clearly the consequence of modi®cation at serine 166 and 186, the consensus sites recently shown to be phosphorylated by Akt (Mayo and Donner, 2001; Zhou et al., 2001) .
Results

Association of HDM2 and Akt in cells
Previous studies have shown that Mdm2 expression is regulated in response to growth factor stimulation of mouse cells (Leri et al., 1999; Shaulian et al., 1997) and involves regulation of the mdm2 promoter through activation of the Ras/Raf/MEK/MAPK pathway (Ries et al., 2000) . We show here, that in response to IGF-1 treatment of primary human ®broblast cells (MRC-5), over a time course, endogenous HDM2 protein expression increases at around 1 h post-stimulation ( Figure 1a ). This increase correlated with activation of Akt phosphorylation on Ser 473 (Figure 1a) . Immunoprecipitation analysis revealed that the endogenous HDM2 and Akt proteins physically associated in response to IGF-1 treatment at this time point ( Figure  1b) . Similarly, following overexpression of both proteins in U2OS or p53/Mdm2 null mouse embryo ®broblasts (MEFS), the two proteins physically associated and HDM2 protein expression was higher in the presence of Akt (Figure 1c ).
Stabilization of MDM2 in response to activation of PI3kinase
The results in Figure 1a indicated that serum stimulation enhanced the expression of endogenous HDM2. To determine whether this eect was mediated through the activation of the PI3 kinase/Akt pathway, and whether it was a re¯ection of enhanced protein a b c d Figure 1 Akt associates with HDM2 in response to IGF-1 stimulation of primary human ®broblasts. (a) MRC-5 cells were grown in the absence of serum for 6 ± 8 h and treated with human IGF-1 (50 ng/ml) for the times indicated. Western blot analysis of whole cells lysates was carried out, to assess HDM2 and Akt protein, using speci®c antibodies to human HDM2 (Ab-1), and phosphorylated Akt (Ser 473). Blots were reprobed with anti-actin to assess loading. (b) MRC-5 cells were grown in the absence of serum for 6 ± 8 h and treated with LLnL (10 mM) for 3 h prior to treatment with human IGF-1 (50 ng/ml) for the times indicated. Cells were lysed and HDM2-speci®c complexes were immunoprecipitated using antibodies to HDM2 (Ab-1). Blots were probed with antibodies to phosphorylated Akt (Ser 473), to assess association and then reprobed with anti Akt (C-terminal antibody) to assess total protein. (c) U2OS, or p53/Mdm2 null MEFS were transiently transfected with HDM2 (9 mg), in the presence or absence of Akt (5 mg). Cells were also cotransfected with pEGFP-N1 (1 mg) as a control. Cells were lysed and HDM2-speci®c complexes were immunoprecipitated using antibodies to HDM2 (Ab-1). Immunoprecipitates were Western blotted and probed with antibodies to phosphorylated Akt (Ser 473), to assess association. Total cell lysates were probed for GFP expression to ensure equal transfection eciency 
Akt phosphorylates HDM2 in vitro
The ability of Akt to physically associate with HDM2, in response to IGF-1 stimulation or by overexpression, led us to examine whether Akt could phosphorylate HDM2. To address this, we performed an in vitro kinase assay using bacterially expressed GST ± HDM2 as a substrate for puri®ed activated Akt ( Figure 3a ). We also observed that Akt was unable to phosphorylate GST control protein in vitro (Figure 3b ), indicating the speci®city of Akt for HDM2 within the GST fusion protein (Figure 3a ,b). GST ± HDM2 was also phosphorylated in a dose-dependent fashion ( Figure 3c ). Importantly, to ensure that Akt speci®cally phosphorylated GST ± HDM2 in this assay, rather than a contaminating kinase, a puri®ed unactivated form Akt was also used. This was unable to autophosphorylate or phosphorylate GST ± HDM2 in vitro, indicating the speci®city of the Akt kinase for phosphorylating GST ± HDM2 ( Figure 3d ). As a negative control, p53 protein was shown not to be phosphorylated by the activated Akt ( Figure 3d ).
Stabilization of MDM2 phosphorylation site mutants
Two recent publications have identi®ed serine 166 and 186 in HDM2 as targets for phosphorylation by Akt (Mayo and Donner, 2001; Zhou et al., 2001 ). Since we also found that Akt can phosphorylate HDM2, and that the two proteins associate with each other following serum stimulation, we considered the possibility that phosphorylation of HDM2 at serine 166 and 186 may lead to the stabilization of the protein. Zhou et al. (2001) showed that substitution of serine 166 and 186 for aspartic acid could mimic the eect of Akt phosphorylation and so we also generated HDM2 ± S166D, HDM2 ± S186D and HDM2 ± S166/ 186DD mutants. Substitution of both serine 166 and 186 for aspartic acid did not lead to enhanced expression of the protein, compared with wild-type HDM2 and the levels of the HDM2 ± S166/186DD mutant protein were reduced in serum starved cells to the same levels as the wild-type HDM2 protein ( Figure  4a ). Furthermore, the HDM2 ± S166D, HDM2 ± S186D and HDM2 ± S166/186DD mutant proteins were all stabilized following co-expression of p14 ARF , a protein that binds and stabilizes HDM2 (Stott et al., 1998) , to levels that were essentially identical to that seen with wild-type HDM2 (Figure 4b ). Taken together, these results suggested that phosphorylation of HDM2 at serine 166 and 186 was not sucient for stabilization of the protein, and led us to investigate whether HDM2 may contain another site for Akt phosphorylation.
HDM2 is phosphorylated by Akt at Ser166, and at a position distinct from the second consensus site at Ser186
To identify the Akt site(s) of phosphorylation within HDM2, we performed an in vitro kinase assay as described above. The 32 P-radioactively-labelled GST ± HDM2 was separated by SDS-polyacrylamide gel, cut out, eluted, and digested with trypsin. The tryptic peptide fragments were separated by reverse ± phase high performance liquid chromatography (HPLC), and eluted fractions were counted as described in the Materials and methods. At least four separate peaks of activity were identi®ed (Figure 5a ). The fractions with highest activity from each of the major peaks (1 ± 4) were pooled separately, and the tryptic peptides isolated from each peak were then subjected to phosphoamino-acid analysis (Figure 5b ). This analysis a b Figure 2 Stabilization of HDM2 in response to activation of the PI3 kinase pathway. (a) MRC-5 cells were transiently transfected with wild type HDM2 (9 mg), and grown in serum free media, either in the absence or presence of IGF-1 (50 ng/ml) or the PI3 kinase inhibitor LY294002, for 6 ± 8 h and harvested for Western blot analysis to assess HDM2 expression. pEGFP-N1 (1 mg) was co-transfected as transfection control. (b) Cells were transiently transfected with wild-type HDM2, serum starved and treated with IGF-1 as described in (a), prior to immunostaining with antibodies to HDM2 (Ab-1). Nuclei were visualized using DAPI showed that the major sites of Akt phosphorylation within HDM2 were on serine.
To determine whether serine 166 and 186 were the major sites for phosphorylation by Akt in vitro, the phosphorylated peptides isolated from peaks 1, and 2 were subjected to automated Edman degradation in a spinning cup sequencer. We were able to determine that the phosphorylated serine residue within the tryptic peptide isolated from peak 1, was located at position 3 within the peptide (Figure 6a ). Further analysis revealed that addition of a peptide spanning serine 166 reduced phosphorylation of GST ± HDM2 by Akt in vitro (Figure 6b ). Taken together, these observations were consistent with phosphorylation at the consensus Akt site at serine 166. Sequencing of the phosphopeptides isolated from peak 2 however, indicated that phosphorylation occurred at positions that did not support serine 186 as the major site of phosphorylation within peak 2.
To support the results obtained by phosphopeptide sequencing, we generated HDM2 mutants containing alanine substitutions at either serine 166 or 186. As previously shown, mutation of serine 166 or 186 alone did not abolish phosphorylation by Akt (Zhou et al., 2001 ) although in our hands mutation of serine 166 slightly reduced the eciency of phosphorylation (data not shown). HPLC analysis of the tryptic peptides of the HDM2 ± S166A mutant protein isolated after Akt phosphorylation in vitro, showed a complete loss of activity from peak 1 (Figure 7a ), Radioactively labelled SDS-polyacrylamide gels were transferred to PVDF membrane, and exposed to ®lm to visualize phosphorylated HDM2, and Akt. Blots were probed with antibodies to HDM2, and Akt to assess protein loading. (b) In vitro kinase assay of bacterially expressed wild-type GST protein as described above. Radioactively labelled SDS-polyacrylamide gels were transferred to PVDF membrane, and exposed to ®lm to visualize any phosphorylated GST, and Akt. Akt does not phosphorylate GST alone. Blots were probed with antibodies to GST to assess protein loading. (c) In vitro kinase assay as described in (a), with increasing amounts of HDM2, as indicated. (d) In vitro kinase assay of bacterially expressed HDM2, or p53, using active or inactive forms of Akt thereby further con®rming that serine 166 is a target for phosphorylation by Akt. Surprisingly however, mutation of serine 186 to alanine (HDM2 ± S186A) did not substantially alter the pattern of Tryptic peptide fragments obtained after phosphorylation with Akt (Figure 7b ), although there was a possible loss of one of the minor peaks. Taken together, these results suggest that an additional Akt phosphorylation site in HDM2 remains to be identi®ed.
Discussion
In this study, we have shown that HDM2 binds to Akt in response to growth factor stimulation of normal cells, and is concurrent with phosphorylation of Akt at Ser 473. This correlated with an enhanced stability of the Akt protein that is dependent on PI3 kinase activity but not phosphorylation of HDM2 at serine 166 and 186. The HDM2 protein is well known for its role in negatively regulating p53 function. In response to dierent stress signals, HDM2 expression, localization and modi®cation are regulated to in¯uence p53 function (Woods and Vousden, 2001 ). However, HDM2 has potent oncogenic activity in its own right (Freedman et al., 1999) and has been shown to be regulated by the Ras/Raf/MEK/MAPK pathway in a p53 independent manner (Ries et al., 2000) . The possibility that HDM2 expression, localization and modi®cation are also regulated in a normal cell to in¯uence p53 function was of particular interest to us in this study. The observation that HDM2 expression levels are enhanced by growth factors has been shown previously, and con®rmed here (Leri et al., 1999; Shaulian et al., 1997) . We were also able to show that the serine-threonine kinase, Akt, physically associated with HDM2 in response to IGF-1 treatment of normal cells, and that this was concurrent with phosphorylation of Akt. These data are consistent with two recent Figure 4 Stability of HDM2 ± S166/186DD mutants. (a) U2OS cells transiently transfected with wild-type HDM2 or HDM2 ± S166/186DD were cultured in serum (+) or serum starved for 12 h (7). The levels of HDM2 protein was assessed by Western blotting, pEGFP-N1 (1 mg) was co-transfected as transfection control. (b) U2OS cells transiently transfected with the indicated HDM2 expression constructs with or without p14 ARF . The levels of HDM2 protein was assessed by Western blotting, pEGFP-N1 (1 mg) was co-transfected as transfection control (Mayo and Donner, 2001; Zhou et al., 2001) The increase in HDM2 protein levels in response to activation of the PI3 kinase/Akt pathway led us to investigate whether phosphorylation of HDM2 at the two Akt consensus sites serine 166 and serine 186 could account for the enhanced protein stability. The observation that substitution of these residues to aspartic acid did not result in elevation of protein levels, and that these mutant proteins remained sensitive to stabilization by growth factor stimulation or p14 ARF binding, suggested that these sites were not responsible for the enhanced HDM2 protein expression seen after activation of Akt. We therefore carried out mapping studies on the phosphorylated protein, by performing Tryptic peptide analysis by reverse phase HPLC, and phosphoamino-acid analysis. Serine to alanine substitution at residue 166 completely abolished the activity from one of the major peaks from our HPLC pro®les, con®rming that serine 166 was indeed an Akt phosphorylation site. Interestingly, our data also suggested that at least one other site that was not the second Akt consensus site at serine 186 could be phosphorylated. In preliminary studies we have found that an HDM2 protein encompassing residues 1 ± 162 is eciently phosphorylated by Akt in vitro (Weber and Vousden, unpublished observations). We are now identifying this site, and will assess the contribution of phosphorylation at this site to HDM2 stability and function.
Materials and methods
Expression of GST-tagged proteins
Mutant GST ± HDM2-S166A, and -S186A, were generated from wild-type GST ± HDM2 (Fang et al., 2000) using the QuickChange Site-directed Mutagenesis kit (Stratagene), in accordance with manufacturer's instructions. BL21 E. coli cells (Novagen), were transformed with the respective GST constructs, BL21 cultures (LB broth) were grown at 378C to approximately log phase, and protein expression was induced by addition of IPTG (100 mM ®nal concentration). Cells were harvested at 3 h post-induction, brie¯y sonicated in lysis buer (supplemented with, PMSF) supernatants containing the respective GST ± HDM2 protein were analysed by 10% 
In vitro kinase assays
Akt kinase assays were carried out, based on those described previously (Ashcroft et al., 1999) . Wild-type GST ± HDM2, S166A and S186A proteins were immunoprecipitated from BL21 cell lysates by addition of 50 ml of a 50% slurry of Glutathione-Sepharose 4B beads (GIBCO ± BRL). Samples were incubated for 1 ± 4 h at 48C with gentle rocking. Samples were washed three times with lysis buer and once with kinase assay (20 mM HEPES pH 7.4, 10 mM MgCl 2 , and 10 mM MnCl 2 ). Kinase assay buer (containing 10 mM [g-32 P]ATP, and either 0.5 mg activate or kinase inactive forms of Akt, UBI) was added to each sample, and incubated at room temperature for 30 min. Samples were resolved on 10% SDS-polyacrylamide electrophoresis, and gels were exposed to X-ray ®lm. Lysates harvested from BL21 cells expressing GST alone were also assayed, to con®rm that Akt did not phosphorylate GST protein.
Reverse-phase HPLC and phospho-amino acid analysis
Wild-type GST ± HDM2 was phosphorylated by Akt in vitro, as described above, separated by 10% SDS ± PAGE, and exposed to X-ray ®lm. The phosphorylated GST ± HDM2 full-length protein was cut out, and eluted from the gel slice in buer containing (50 mm ammonium bicarbonate, pH 8.0, 0.1% SDS and 0.1% b-mercaptoethanol) at 378C. The eluted protein was acid-precipitated, oxidized, then digested with sequencing grade trypsin for approximately 16 h at 378C as described elsewhere (Morrison et al., 1993) . Tryptic peptides were isolated by reverse-phase HPLC on a C18 column. Fractions were eluted at 1 ml/min with an increasing gradient of acetonitrile at 0 ± 30% CH 3 CN for 90 min, 30 ± 60% CH 3 CN for 5 min and 60% CH 3 CN for 5 min. One ml fractions were collected and counted for [ 32 P] content in a Beckman LC 5801 scintillation counter. For phospho-amino acid analysis, fractions within each peak highest counts were pooled, lyophilized, and hydrolyzed with 5.7 N HCl for 1 h at 1108C. The recovered phospho-amino acids were subjected two-dimensional separation, as described elsewhere (Morrison et al., 1993) . For sequencing by solid phase Edman degradation, semi-automated amino-terminal sequence analysis was performed on Sequalon disks in a Model 420 Applied Biosystems sequencer, as described elsewhere (Morrison et al., 1993) .
Analysis of HDM2 in cells
Normal human diploid ®broblasts (MRC-5 cells), U2OS or p53/Mdm2 null mouse embryo ®broblasts were maintained in RPMI or DMEM media (GIBCO ± BRL) containing 10% foetal calf serum. Cells (0.8610 6 ) were plated onto 10 cm 2 dishes approximately 16 h prior to washing twice in serum free media. Cells were starved for approximately 6 ± 8 h, then stimulated with recombinant human IGF-1 at 50 ng/ml (Sigma). Cells were harvested at 0, 15, 30, 60 min and 4 h post-IGF-1 treatment in NP40 lysis buer as described previously . Where indicated, cells were incubated with LLnL (calpain inhibitor I, 50 mM) for 3 h prior to IGF-1 stimulation. For experiments using the PI3 kinase inhibitor, cells were incubated in serum free medium prior to pre-treatment for 30 min with or without LY294002 Figure 7 Mutational analysis at serine 166 and serine 186. Graphs illustrating the total speci®c activity (c.p.m.) of eluted fractions from the HPLC analysis of Tryptic peptides of either wild-type HDM2 and HDM2-S166A (a) or wild-type HDM2 and HDM2-S186A (b) proteins. Peaks 1 and 2 indicate major peaks of activity. Peak 1, is lost when serine 166 is mutated to alanine, indicated by an arrow (10 mM) and subsequent treatment with IGF-1 as described above. HDM2 protein complexes were immunoprecipitated using monoclonal anti-HDM2 (0.5 mg, Ab-1, Calbiochem), and ProteinG Sepharose beads (Pierce), as described previously . Complexes were resolved by 10% SDS ± PAGE, and assessed by Western blot analysis using a monoclonal anti-HDM2 (Ab-1, Oncogene Science/ Calbiochem), a polyclonal anti-phospho-Akt (Ser 473, NEB), or a polyclonal anti-Akt antibody raised to a C-terminal peptide (C-RPHFPQFSYSASSTA), as previously described (Franke et al., 1997) . Blots were re-probed with a monoclonal anti-beta actin antibody (Calbiochem) to assess loading. Transient transfection experiments were carried out using wild-type Akt, HDM2, p14 ARF , and GFP expression plasmids as previously described (Kane et al., 1999; Chen et al., 1995; Lohrum et al., 2000) . HDM2 ± S166D, HDM2 ± S186D and HDM2 ± S166/186DD mutants were generated from wild-type pCHDM1A (Chen et al., 1995) using the QuickChange Site-directed Mutagenesis Kit (Stratagene). In transient overexpression assays, we observed that full-length Akt, when overexpressed, was phosphorylated at Ser 473 above background levels as detected by Western, although this activation was not as marked as observed for the transiently expressed myristylated version of Akt.
Immunostaining
Normal human diploid ®broblasts (MRC-5 cells) were maintained in RPM1 media (GIBCO ± BRL) containing 10% foetal calf serum. Cells (0.8610 6 ) were plated onto 10 cm 2 dishes approximately 24 h prior to transient transfection with either control vector, or wild-type HDM2 as described above. Cells were washed twice in serum free media approximately 16 h post-transfection, and maintained in serum-free media or serum-free media supplemented with 50 ng/ml IGF (Sigma) for approximately 6 ± 8 h. Cells were ®xed and stained for HDM2 using a monoclonal anti-HDM2 (Ab-1, Oncogene Science/Calbiochem) as described previously .
